HomeNEO • NASDAQ
add
NeoGenomics, Inc.
Previous close
$9.69
Day range
$9.42 - $9.95
Year range
$4.72 - $19.11
Market cap
1.26B USD
Avg Volume
4.37M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Revenue | 187.80M | 11.90% |
Operating expense | 99.27M | 11.60% |
Net income | -27.13M | -53.28% |
Net profit margin | -14.45 | -36.97% |
Earnings per share | 0.03 | -40.00% |
EBITDA | -2.39M | -161.15% |
Effective tax rate | -2.80% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 164.12M | -57.68% |
Total assets | 1.37B | -16.23% |
Total liabilities | 536.49M | -26.80% |
Total equity | 838.29M | — |
Shares outstanding | 129.39M | — |
Price to book | 1.49 | — |
Return on assets | -3.40% | — |
Return on capital | -3.74% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Net income | -27.13M | -53.28% |
Cash from operations | 8.88M | -3.92% |
Cash from investing | -277.00K | 92.12% |
Cash from financing | 765.00K | -35.00% |
Net change in cash | 9.39M | 36.01% |
Free cash flow | 14.48M | 124.89% |
About
NeoGenomics Laboratories, Inc., also known as NeoGenomics or Neo, is an American CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. The company's testing services include cytogenetics, fluorescence in situ hybridization, flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics.
Headquartered in Fort Myers, FL, NeoGenomics maintains a network of testing facilities across the US, with laboratories in Florida, California, Tennessee, and Texas. Wikipedia
Founded
2002
Headquarters
Website
Employees
2,200
